SEC Form 4 · accession 0001209191-18-061538
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James J Vaughn
Officer — Chief Commercial Officer
Period of report
Dec 6, 2018
Accepted (ET)
Dec 7, 2018 · 5:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 6, 2018 | M | 3,000 | $31.12 | A | 20,763 | D | |
| Common StockF2,F3,F4,F1 | Dec 6, 2018 | S | 300 | $73.7533 | D | 20,463 | D | |
| Common StockF2,F3,F5,F1 | Dec 6, 2018 | S | 1,596 | $75.293 | D | 18,867 | D | |
| Common StockF2,F3,F6,F1 | Dec 6, 2018 | S | 1,104 | $75.72 | D | 17,763 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy) HoldingF7 | $31.12 | Dec 6, 2018 | M | 3,000 | D | — | Feb 13, 2025 | Common Stock | 3,000 | 33,772 | D |
Explanation of responses
- F1Includes an aggregate of 15,534 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 6, 2018.
- F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F4Represents weighted average sale price. Actual sale prices ranged from $73.12 to $74.07.
- F5Represents weighted average sale price. Actual sale prices ranged from $74.55 to $75.53.
- F6Represents weighted average sale price. Actual sale prices ranged from $75.58 to $76.11.
- F7The option became exercisable as to 25% of the shares on February 13, 2016, and becomes exercisable as to 1/48th of the shares each full month thereafter.